Updated results of a prospective noninterventional study of everolimus after failure of the first VEGF-targeted therapy.
Michael D. Staehler
Consultant or Advisory Role - Bayer; GlaxoSmithKline; Novartis; Pfizer
Peter J. Goebell
Consultant or Advisory Role - Novartis
Ulrich Kube
No relevant relationships to disclose
Manfred Kindler
No relevant relationships to disclose
Thomas Koepke
No relevant relationships to disclose
Jan Janssen
No relevant relationships to disclose
Joerg Schmitz
No relevant relationships to disclose
Steffen Weikert
No relevant relationships to disclose
Susanne Kloss
No relevant relationships to disclose
Gabriel Steiner
No relevant relationships to disclose
Andreas Jakob
Consultant or Advisory Role - Novartis
Thomas Steiner
Consultant or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Novartis; Pfizer
Friedrich Overkamp
Consultant or Advisory Role - Novartis
Lothar Bergmann
Consultant or Advisory Role - Novartis
Gernot Guderian
Employment or Leadership Position - Novartis
Christian Doehn
Consultant or Advisory Role - GlaxoSmithKline; Novartis